OCTAPHARMA
13.7.2020 13:39:07 CEST | Business Wire | Press release
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020.
The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final results of the study showed a cumulative incidence of high-titre anti-FVIII inhibitors of 17.6%. Patients who completed the NuProtect study were offered participation in a long-term extension study (NCT01992549). The results of the extension study will be presented for the first time at ISTH 2020.
In patients who develop inhibitors, immune tolerance induction (ITI) with repeated FVIII administration is the only proven approach to eradicate inhibitors. Three posters will be presented at ISTH 2020 reporting on the success of ITI with two of Octapharma’s FVIII products, octanate® and Nuwiq® .
The titles of the posters are provided below. All abstracts are available on the ISTH website .
Poster PB0999 Long-term immunogenicity, efficacy and safety of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect PUP study
Poster PB1001 Immune tolerance induction (ITI) with a single factor VIII/von Willebrand factor concentrate in haemophilia A patients with inhibitors - Update from the ObsITI Study
Poster PB1044 Immune tolerance induction with octanate® in patients with haemophilia A and inhibitors: An ongoing case series from a Malaysian centre
Poster PB1047 Immune tolerance induction with simoctocog alfa in patients with haemophilia A: An ongoing multicentre case series from the UK
Octapharma will be sponsoring two scientific symposia at ISTH 2020 on haemophilia A and von Willebrand disease (VWD). The haemophilia A symposium will include new clinical and real-world data on Nuwiq® , including final results from the NuProtect study and its long-term extension as well as experience with personalized prophylaxis in previously treated patients. New studies of ITI and the relevance of FVIII in managing joint and bone health will also be discussed. The VWD symposium will address the challenges of diagnosing VWD and particular issues facing women with VWD, as well as discussing the use of wilate® for prophylaxis and during surgery.
Both symposia will be held on Tuesday 14 July (8:45 am EDT and 10:15 am EDT) on the ISTH virtual congress platform and will be freely available to all healthcare professionals. The symposia will remain on the congress platform for 90 days and be available on the ISTH Academy website for one year.
“We are very pleased to share the positive data across our product portfolio addressing the needs of individuals with haemophilia and von Willebrand disease”, said Dr Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “the data cover the large spectrum of care required by patients with coagulation disorders, and demonstrate Octapharma’s commitment to improving patients’ lives at an individual level .”
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US. More information on www.octapharma.com
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1 . It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1 . Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1 . Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2 . Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2 .
- Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
- Nuwiq® Summary of Product Characteristics.
About wilate®
wilate® is a high-purity human von Willebrand factor/factor VIII (VWF/FVIII) concentrate, that undergoes two virus inactivation steps during its production.1 No albumin is added as a stabiliser1 . The purification processes result in a 1:1 ratio of VWF to FVIII that is similar to normal plasma1 . wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma1 . wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres2 . wilate® is available in 500 IU and 1000 IU presentations. wilate® is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) 2 .
- Stadler M et al. Biologicals 2006; 34:281-8.
- wilate® Summary of Product Characteristics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005330/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swedish Court Further Reschedules Delivery of Judgment in PriceRunner Vs Google Antitrust Case24.6.2026 20:55:00 CEST | Press release
Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has again postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from June 26, 2026 to July 1, 2026 at 13:00 CET. As with the Court's two previous notifications, the rescheduling is a procedural decision by the Court and relates solely to the timing of the judgment delivery. In its notification, the Court cited high workload as the reason for needing additional time to finalize the judgment. No inference about the outcome should be drawn from it. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former P
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 16:00:00 CEST | Press release
Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 15:30:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives backs Taktile as a leading enabler of AI-driven efficiency and performance gains in banks and insurers. Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insur
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 15:25:00 CEST | Press release
Multinational study finds preparedness, early life experiences, and community support play a critical role in building resilience and confidence, reinforcing MetLife’s purpose. Sports, education, and mentorship at a young age shape long-term confidence and resilience. MetLife and MetLife Foundation are supporting initiatives like the FIFA Global Citizen Education Fund to expand access to education and sports programs for youth in communities worldwide, supporting their future success. A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 15:08:00 CEST | Press release
Simple, user-friendly product enables effective cytology cell concentration without complex steps, integrating seamlessly into existing pathology workflows. StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom